Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease
Listen now
Description
In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease.
Related Content:
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease Donanemab in Early Symptomatic Alzheimer Disease
More Episodes
The Federal Trade Commission’s (FTC) oversight role in the pharmaceutical market is critical to the health of patients and the health care system. Aaron Kesselheim, MD, JD, MPH, and JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, discuss the FTC’s policies and legal actions related to...
Published 05/20/24
Published 05/20/24
Do text messages with or without financial incentives increase weight loss in men with obesity? Pat Hoddinott, MB, BS, PhD, of Stirling University talks with JAMA Deputy Editor Mary McGrae McDermott, MD, about the results of a randomized clinical trial that tested whether financial incentives...
Published 05/14/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
